Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine,
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
The impact of this deal on the stock market has been quite bullish, especially for AI-related companies and those involved in ...
CNBC on MSN11d
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billionShares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of ...
In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...
1hon MSN
Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...
David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...
Larry Ellison unveiled plans for an AI-driven cancer vaccine system that could deliver personalized treatments within 48 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback